AGS PSCA
/ Astellas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 12, 2011
Improved 6-month survival rate in subjects with prostate stem cell antigen (PSCA) positive tumours in a global, randomized phase 2 trial comparing gemcitabine vs. gemcitabine + Ags-1c4d4 (asp6182) in metastatic pancreatic cancer (mPC)
(ECCO-ESMO 2011)
- 2008002; P2, N=205; A trend toward improved 6-mo SR was seen in mPC patients with tumours that stained strong or moderate for PSCA expression who were treated with gemcitabine (57%) or gemcitabine + Ags-1c4d4 (74%)
P2 data • Pancreatic Cancer
1 to 1
Of
1
Go to page
1